

11<sup>th</sup> February, 2026

**To,**  
 The Manager  
 Listing Department  
 National Stock Exchange of India Limited  
 Exchange Plaza, 5th Floor  
 Plot No. C-1, Block G  
 Bandra Kurla Complex, Bandra (E)  
 Mumbai – 400 051.

**NSE Symbol: AAKAAR**

**Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Product Launch information.**

Dear Sir/Madam,

Further to our letter dated 13.8.2025 and pursuant to Regulation 30 read with Para B of Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. SEBI/HO/CFD/PoD/CIR/P/2023/120 dated July 13, 2023, details with respect to the following product launch are disclosed as under:

| Sr. No.          | Name of the Product | Date of Launch | Category of Product | Whether caters to domestic/ international market | Name of the countries in which the product is launched (in case of international) |
|------------------|---------------------|----------------|---------------------|--|---|
| V.M. Corporation |                     |                |                     |  |   |
| 1                | Exosignal Hair      | 23-12-2025     | Professional Use    | Domestic   | -   |
| 2                | V Tech System       | 23-12-2025     | Professional Use    | Domestic   | -   |
| 3                | Exo V Slim System   | 23-12-2025     | Professional Use    | Domestic   | -   |
| 4                | V Carbon System     | 23-12-2025     | Professional Use    | Domestic   | -   |
| 5                | Z K Face            | 23-12-2025     | Professional Use    | Domestic   | -   |
| 6                | Exocell Mask        | 23-12-2025     | Professional Use    | Domestic   | -   |
| 7                | Exotech gel         | 23-12-2025     | Homecare            | Domestic   | -   |



CIN No.: L74900MH2013PLC244717

**Aakaar Medical Technologies Limited**  
(formerly: Aakaar Medical Technologies Pvt.Ltd.)  
A-801, Heritage Plaza, Teli Gali Cross Road  
Andheri (East), Mumbai – 400 069 INDIA  
Mob: + 91 9820317468  
E-mail: [info@akaarmedical.in](mailto:info@akaarmedical.in)  
[www.akaarmedical.in](http://www.akaarmedical.in)  
GST No: 27AALCA7587Q1ZK

A press release of the same is also enclosed to this intimation and will also be made available on the Company's website at [www.akaarmedical.in](http://www.akaarmedical.in)

You are requested to take the above information on your record.

Thanking you,

Yours faithfully,  
For Aakaar Medical Technologies Limited,

Anoopkumar Pillai  
Company Secretary & Compliance Officer

Encl.: As above

## **Press Release**

Aakaar Medical Technologies has officially signaled a new era in Indian aesthetics with the launch of the country's first Synthetic Exosome platform. In a strategic first-mover partnership with VM Corporation, Italy, Aakaar introduced this breakthrough technology through landmark scientific events on December, 23, 2025 in Goa, January 16, 2026 in Delhi and January 17, 2026 in Mumbai, attended by the nation's leading dermatologists.

### **The Shift: From Volume to Cellular Function**

In 2026, regenerative medicine surpassed traditional treatments like fillers or toxins to become the industry gold standard. Today's patients prioritize high-fidelity results, seeking to improve skin elasticity, thickness, and biological glow rather than merely filling gaps.

This cell-free revolution moves away from live stem cell therapies, which carry significant ethical and regulatory hurdles, toward Exosomes. These tiny extracellular vesicles act as the messengers of the cellular world. Unlike stem cells, these vesicles do not replicate. Instead, they signal the body's own fibroblasts to ramp up collagen production and reverse the effects of "inflammaging."

### **Solving the Purity and Stability Bottleneck**

Aakaar's introduction of VM Corporation's synthetic exosomes, produced via the patented SuperExo™ process, addresses the critical limitations of human or animal-derived products.

- **Standardization:** It eliminates the batch-to-batch inconsistency and donor variability found in biological sources.
- **Stability:** The platform provides a sterile, shelf-stable product that removes the risks of biological contamination.
- **Ethics and Compliance:** It bypasses the complex regulatory landscape of stem-cell products, offering a scientifically engineered alternative for the modern Indian patient.

### **Landmark Scientific Launches**

The launch events featured the VM Corporation leadership team from Milan, including Elena Belova (General Director), Martina Conato (Sales Manager), and Dr. Pasquale Ruggerio (Renowned Plastic Surgeon and KOL).

- **In Delhi:** A ceremonial unveiling was led by eminent dermatologists Dr. Rashmi Sarkar, Dr. Meghna Gupta, Dr. Gulhima Arora, and Dr. Sandeep Babbar, marking the formal arrival of standardized exosome technology.
- **In Mumbai:** Dr. Madhuri Agarwal moderated a forward-looking panel titled "What Will Define the Gold Standard in Exosome Therapy Over the Next 5 Years?" The panel featured distinguished dermatologists Dr. Aseem Sharma and Dr. Rachita Dhurat, alongside



CIN No.: L74900MH2013PLC244717

**Aakaar Medical Technologies Limited**  
(formerly: Aakaar Medical Technologies Pvt.Ltd.)  
A-801, Heritage Plaza, Teli Gali Cross Road  
Andheri (East), Mumbai – 400 069 INDIA  
Mob: + 91 9820317468  
E-mail: info@aakaarmedical.in  
www.aakaarmedical.in  
GST No: 27AALCA7587Q1ZK

prominent plastic surgeons Dr. Viral Desai and Dr. Pasquale Ruggerio, who provided a multidisciplinary perspective on regenerative aesthetics.

### **Strategic Market Leadership: The Exovea Division**

Through its newly launched Exovea division, Aakaar Medical Technologies intends to capture the premium regenerative market with a portfolio including VM ExoSignal Hair and the V-Tech System.

With the Indian aesthetic market growing at a 14% CAGR, Aakaar's move into high-margin Italian technology positions the company to lead its projected INR 6 Crore revenue target for the Exovea division in its inaugural year. By combining synthetic exosomes with biomimetic peptides, Aakaar is setting a new benchmark for safety and efficacy in hair restoration and skin rejuvenation.

For Aakaar Medical Technologies Ltd.

Dr. Rahul B. Sawakhande  
CEO & Director  
Mumbai,  
11.02.2026